Arvinas To Present Preclinical Data For Its PROTAC BCL6 Degrader, ARV-393, In Combination With Glofitamab At 2025 American Society Of Hematology Annual Meeting

Author: Benzinga Newsdesk | November 03, 2025 04:02pm

NEW HAVEN, Conn., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (NASDAQ:ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that preclinical data for PROTAC BCL6 degrader ARV-393, in combination with glofitamab, a CD20xCD3 bispecific antibody, will be presented in a poster presentation at the 2025 American Society of Hematology (ASH) Annual Meeting, being held December 6–9, 2025, in Orlando, Florida.

The presentation details are as follows:

• Session Name: 605. Molecular Pharmacology and Drug Resistance: Lymphoid Neoplasms: Poster I
• Date: December 6, 2025
• Time: 5:30 PM – 7:30 PM ET
• Room: OCCC – West Halls B3–B4
• Publication Number: 1520
  
   

The full abstract can be accessed via the ASH online program.

About ARV-393

ARV-393 is an investigational PROteolysis TArgeting Chimera (PROTAC) designed to degrade B-cell lymphoma 6 protein (BCL6), a transcriptional repressor and major driver of B-cell lymphomas. The BCL6 protein facilitates B cell tolerance of rapid proliferation and somatic gene recombination via repressing cell cycle checkpoints, terminal differentiation, apoptosis, and the DNA damage response. PROTAC-mediated degradation has the potential to address the traditional undruggable nature of BCL6. ARV-393 is currently being evaluated in a Phase 1 clinical trial in patients with non-Hodgkin lymphoma.

Posted In: ARVN